Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ising lantibiotic candidates in pre-clinical testing for the treatment of Gram-positive infections including MRSA and novel broad spectrum bacteriocins for the treatment of both Gram-positive and Gram-negative infections.

Following the completion of the investment, Novacta will appoint Dr. Richard Garraway and Dr. Bob Milsted, both partners of CPHA, to its Board of Directors. In a further Board change, the Chairman Dr. Andrew Sandham will retire from the Board on completion and will be replaced by Dr. Andy Richards. The new directors bring significant drug development, financial and corporate development experience to Novacta.

Commenting on the investment, John Mayo, Managing Partner of CP2 said: "The urgent need for new antibiotics is well known, Novacta represents a real opportunity to meet this significant unmet medical need in C. difficile infection, MRSA and related Gram-positive infections and Gram-negative infections, such as E. coli and Salmonella. Our investment in Novacta fits our model of taking a majority position in high quality companies with well differentiated technologies and bringing both funding and additional commercial, regulatory, drug development and manufacturing experience to increase both the probability of success and the value of the products. We are looking forward to working with the dynamic management team at Novacta under Tony Sedgwick, producing important new antibiotics and a great return for existing Novacta shareholders and Celtic Pharma investors alike."

Stephen Parker, a Partner in CP2 added: "This is the second in a series of major investments in high-quality UK biotech companies. We were delighted to see the announcement from the UK Government this week of the creation of the Innovation Investment Fund-of-funds to invest in technology-based businesses and we look forward to helping the Government fulfil its ambitions in the UK life science sector as we continue
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... Pittcon is pleased to announce that the 2015 ... Scientific, have organized a session on nanotechnology for presentation ... Asia’s largest analytical and scientific instruments show, will be ... , The four speakers in this U.S. symposium, “Thinking ... Single Cells” will present their use of nanotechnology to ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... the food processing industry, is asking industry professionals to ... comparison of the E2 soap they’re currently using to ... Soap . Hand hygiene is critical to fighting ... processing environment. Six key criteria are identified to evaluate ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... funded by Cadila Pharmaceuticals and Revenues from Sales ... in Novavax , ROCKVILLE, Md., March 31 ... today it has formed a joint venture with ... and market vaccines, pharmaceuticals and diagnostic products in ...
... more to attend global event for health care leaders in ... , D.C. ... Congress, April 14-16, Washington, D.C., is pleased to announce several ... with top health leaders from the United States and colleagues ...
... Calif., March 31 Based on its recent ... & Sullivan recognizes Carl Zeiss Meditec with the ... Award for its optical coherence tomography (OCT) technology ... pioneer of OCT technology and has launched clinical ...
Cached Biology Technology:Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 2Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 3Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 4Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 5Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 6Health Care Innovations and Opportunities Attract Attendees from 40 Countries and Delegations from 12 to 6th Annual World Health Care Congress 2Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications 2Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications 3Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications 4
(Date:8/29/2014)... UC Davis have made some surprising discoveries about ... simian immunodeficiency virus (SIV), the team found that ... are early responders to viral invasion and are ... cytokine called interleukin-1 beta (IL-1β). , Though ... breakdown of the gut epithelium that provides a ...
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
Breaking Biology News(10 mins):The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3CCNY team defines new biodiversity metric 2
... that it is launching a new journal, the Journal ... be published bimonthly, and will focus on the advances ... and engineering. The first issue will appear in late ... Engineering will cover the fields of natural gas exploration, ...
... Johns Hopkins and Ohio State University have found that the ... severity of colon cancer in a mouse model. Publishing in ... how trisomy 21, or Down syndrome in humans, can repress ... 50-year-old debate about whether people with Down syndrome develop cancer ...
... you really are is a fairly harmless, socially accepted habit ... matter of life and death for caterpillars of large blue ... one of the ants own larvae. In a publication in ... for Social Evolution (CSE) at the University of Copenhagen show ...
Cached Biology News:Elsevier launches new journal: Journal of Natural Gas Science and Engineering 2Gene dose affects tumor growth 2Smell-wars between butterflies and ants 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Synthetic peptide derived from the internal region ... Specific for the internal region of ... identifies the target band at ~590 kDa. ... secreted media from primary tracheobranchial epithelial cultures ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Biology Products: